U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

Robert F. Kennedy Jr., President Donald Trump's choice to be Secretary of Health and Human Services, appears before the ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

Along with claiming the lives of 1.2 million Americans, the COVID-19 pandemic has been described as a mass disabling event.

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and ...

Meanwhile, in an executive order, Trump created his long-discussed “Department of Government Efficiency,” to be led by Elon ...

Doctors weigh in on the pros and cons of navel pulling, an ancient practice that's going viral because of claims it helps ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.